ArticleFrontiers in endocrinology2025
Elevated serum chromogranin A levels are independently associated with metabolic and inflammatory disturbances in polycystic ovary syndrome.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Polycystic ovary syndrome (PCOS) is a multifactorial endocrine disorder characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology, frequently accompanied by insulin resistance, inflammation, and other metabolic disturbances. Chromogranin A (CgA), a glycoprotein secreted by neuroendocrine cells, has been linked to metabolic regulation and inflammatory processes, but its role in PCOS remains unexplored. This study aimed to evaluate serum CgA levels in women with PCOS and their association with metabolic, hormonal, and inflammatory parameters. Methods: This case-control study included 75 women with PCOS, diagnosed according to the Rotterdam criteria, and 75 age-matched healthy controls, recruited between January and April 2021 at Istanbul Aydın University Medical Park Florya Hospital. Serum CgA levels were measured using ELISA. Clinical parameters and biochemical markers, including glucose, insulin, HOMA-IR, lipid profile, sex hormones, SHBG, and hs-CRP, were assessed. Correlation, multivariate linear regression. Results: Mean serum CgA levels were significantly higher in the PCOS group than in controls (934.68 ± 256.27 vs. 642.27 ± 197.63 pg/mL, p < 0.001). PCOS patients also had higher glucose, insulin, HOMA-IR, triglycerides, hs-CRP, LH, total testosterone, FAI, and DHEA-S, with lower HDL-C and SHBG (all p < 0.05). CgA correlated positively with BMI, glucose, insulin, HOMA-IR, and hs-CRP, and remained independently associated with BMI, HOMA-IR, and hs-CRP in multivariate analysis. In multivariable models, CgA remained independently associated with BMI, HOMA-IR, and hs-CRP. These findings suggest that CgA reflects the metabolic-inflammatory milieu accompanying PCOS rather than indicating PCOS per se. Discussion: Elevated CgA levels in PCOS are independently associated with obesity, insulin resistance, and low-grade inflammation. CgA may serve as a novel biomarker for metabolic risk stratification in PCOS, warranting validation in larger, prospective studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.